Xiao-Ping Li1, Xiao-Wei Zhang2, Lei-Zhen Zheng1, Wei-Jian Guo2. 1. Department of Oncology, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University Shanghai 200092, China. 2. Department of Oncology, Cancer Hospital, Fudan University Shanghai 200032, China.
Abstract
BACKGROUND: CD44 is a potentially interesting prognostic marker and therapeutic target in pancreatic cancer. The expression of CD44 has been reported to correlate with poor prognosis of pancreatic cancer in most literatures. The purpose of this study is to investigate the roles of CD44 in pancreatic caner, and their correlation with the prognosis of pancreatic cancer patients. METHODS: 67 pancreatic cancer samples were collected in Xinhua hospital affiliated to Shanghai Jiaotong University dating from Jan 2010 to Dec 2012. Immunohistochemistry was applied to test the expression of CD44 in pancreatic cancer. The clinical data of the patients were collected including their gender, age, the histology and location, lymph node metastasis and so on. The correlation between the CD44 expression and the clinicopathological factors of patients with pancreatic cancer was analyzed by the software SPSS 13.0. We devise and synthesis of effectively interference of shRNA sequence of CD44, which was transefected to the pancreatic cancer cells PANC-1. Colony formation assay, cell migration assays and western blot were performed. RESULTS: The positive rates of CD44 expression in pancreatic samples were 73.1% (49/67). Univariate analysis showed that there were a significant differences between the CD44 expression and the pancreatic cancer' T staging, TNM staging, lymph node metastasis, the differentiation degree, tumor location (P < 0.05). The Cox proportional hazards model showed that differentiation, CD44 expression and nerve invasion were independent prognostic factors. Knockdown of CD44 expression in pancreatic cancer cells led to decreased cellular proliferation and migration ability, accompanied by downregulation of p-ERK and p-AKT. CONCLUSION: CD44 were related to the distant metastasis and aggressive malignant behaviors of pancreatic cancer. CD44 may regulate tumorigenesis and cancer metastasis partially via PI3K/AKT or MAPK/ERK regulatory pathway.
BACKGROUND:CD44 is a potentially interesting prognostic marker and therapeutic target in pancreatic cancer. The expression of CD44 has been reported to correlate with poor prognosis of pancreatic cancer in most literatures. The purpose of this study is to investigate the roles of CD44 in pancreatic caner, and their correlation with the prognosis of pancreatic cancerpatients. METHODS: 67 pancreatic cancer samples were collected in Xinhua hospital affiliated to Shanghai Jiaotong University dating from Jan 2010 to Dec 2012. Immunohistochemistry was applied to test the expression of CD44 in pancreatic cancer. The clinical data of the patients were collected including their gender, age, the histology and location, lymph node metastasis and so on. The correlation between the CD44 expression and the clinicopathological factors of patients with pancreatic cancer was analyzed by the software SPSS 13.0. We devise and synthesis of effectively interference of shRNA sequence of CD44, which was transefected to the pancreatic cancer cells PANC-1. Colony formation assay, cell migration assays and western blot were performed. RESULTS: The positive rates of CD44 expression in pancreatic samples were 73.1% (49/67). Univariate analysis showed that there were a significant differences between the CD44 expression and the pancreatic cancer' T staging, TNM staging, lymph node metastasis, the differentiation degree, tumor location (P < 0.05). The Cox proportional hazards model showed that differentiation, CD44 expression and nerve invasion were independent prognostic factors. Knockdown of CD44 expression in pancreatic cancer cells led to decreased cellular proliferation and migration ability, accompanied by downregulation of p-ERK and p-AKT. CONCLUSION:CD44 were related to the distant metastasis and aggressive malignant behaviors of pancreatic cancer. CD44 may regulate tumorigenesis and cancer metastasis partially via PI3K/AKT or MAPK/ERK regulatory pathway.
Authors: M M Javle; J F Gibbs; K K Iwata; Y Pak; P Rutledge; J Yu; J D Black; D Tan; T Khoury Journal: Ann Surg Oncol Date: 2007-09-19 Impact factor: 5.344
Authors: Jingli Hao; Michele C Madigan; Aparajita Khatri; Carl A Power; Tzong-Tyng Hung; Julia Beretov; Lei Chang; Weiwei Xiao; Paul J Cozzi; Peter H Graham; John H Kearsley; Yong Li Journal: PLoS One Date: 2012-08-03 Impact factor: 3.240
Authors: Kaidi Mikhitarian; Maressa Pollen; Zhiguo Zhao; Yu Shyr; Nipun B Merchant; Alexander Parikh; Frank Revetta; M Kay Washington; Cindy Vnencak-Jones; Chanjuan Shi Journal: Mod Pathol Date: 2013-11-01 Impact factor: 7.842
Authors: Eduardo Alonso Cruz Monroy; Pedro Paulo de Andrade Santos; Maria Luiza Diniz de Sousa Lopes; Adalberto Mosqueda-Taylor; Leão Pereira Pinto; Lélia Batista de Souza Journal: Histochem Cell Biol Date: 2018-07-03 Impact factor: 4.304
Authors: Juliet Padden; Maike Ahrens; Julia Kälsch; Stefanie Bertram; Dominik A Megger; Thilo Bracht; Martin Eisenacher; Peri Kocabayoglu; Helmut E Meyer; Bence Sipos; Hideo A Baba; Barbara Sitek Journal: Mol Cell Proteomics Date: 2015-12-07 Impact factor: 5.911
Authors: Marius Kemper; Alina Schiecke; Hanna Maar; Sergey Nikulin; Andrey Poloznikov; Vladimir Galatenko; Michael Tachezy; Florian Gebauer; Tobias Lange; Kristoffer Riecken; Alexander Tonevitsky; Achim Aigner; Jakob Izbicki; Udo Schumacher; Daniel Wicklein Journal: J Exp Clin Cancer Res Date: 2021-06-26